---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-23-000047"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:44:16.842973+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q2: revenue $221M, GAAP EPS $0.56, Non-GAAP $0.74; raises FY EPS guidance to $2.65-$2.75

## Summary
- Revenue $221.0M, +45% YoY; GAAP diluted EPS $0.56 vs $0.16 YoY; non-GAAP diluted EPS $0.74 vs $0.53.
- Royalty revenue record $111.7M (+31% YoY), driven by subcutaneous DARZALEX.
- Raised 2023 non-GAAP diluted EPS guidance to $2.65-$2.75 from $2.50-$2.65; revenue guidance $825-$845M.
- FDA approval of VYVGART Hytrulo (argenx) for gMG triggered $33M milestones and royalties.
- Positive Phase 3 data from Roche's SC ocrelizumab and argenx's CIDP trial support pipeline growth.

## SEC filing metadata
- accession: 0001159036-23-000047
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000047/0001159036-23-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000047/halo-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-23-000047
- JSON: https://secwatch.observer/filing/0001159036-23-000047.json
- Plain text: https://secwatch.observer/filing/0001159036-23-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.